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Stephen M. Beard, MSC,k David R. Holmes, JR, MD{ABSTRACTFro
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ma
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MaBACKGROUND Left atrial appendage closure (LAAC) and nonwarfarin oral anticoagulants (NOACs) have emerged as
safe and effective alternatives to warfarin for stroke prophylaxis in patients with nonvalvular atrial ﬁbrillation (AF).
OBJECTIVES This analysis assessed the cost-effectiveness of warfarin, NOACs, and LAAC with the Watchman device
(Boston Scientiﬁc, Marlborough, Massachusetts) for stroke risk reduction in patients with nonvalvular AF at multiple time
points over a lifetime horizon.
METHODS A Markov model was developed to assess the cost-effectiveness of LAAC, NOACs, and warfarin from the
perspective of the Centers for Medicare & Medicaid Services over a lifetime (20-year) horizon. Patients were 70 years of
age and at moderate risk for stroke and bleeding. Clinical event rates, stroke outcomes, and quality of life information
were drawn predominantly from PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Pa-
tients with Atrial Fibrillation) 4-year data and meta-analyses of warfarin and NOACs. Costs for stroke risk reduction
therapies, treatment of associated acute events, and long-term care following disabling stroke were presented in 2015
U.S. dollars.
RESULTS Relative to warfarin, LAAC was cost-effective at 7 years ($42,994/quality-adjusted life-years [QALY]), and
NOACs were cost-effective at 16 years ($48,446/QALY). LAAC was dominant over NOACs by year 5 and warfarin by
year 10. At 10 years, LAAC provided more QALYs than warfarin and NOACs (5.855 vs. 5.601 vs. 5.751, respectively).
In sensitivity analyses, LAAC remained cost-effective relative to warfarin ($41,470/QALY at 11 years) and NOACs
($21,964/QALY at 10 years), even if procedure costs were doubled.
CONCLUSIONS Both NOACs and LAAC with the Watchman device were cost-effective relative to warfarin, but LAAC was
also found to be cost-effective and to offer better value relative to NOACs. The results of this analysis should be considered
when formulating policy and practice guidelines for stroke prevention in AF. (J Am Coll Cardiol 2015;66:2728–39)
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AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
ICER = incremental cost-
effectiveness ratio
LAAC = left atrial appendage
closure
MRS = modiﬁed Rankin score
NOAC = nonwarfarin oral
anticoagulant
PSA = probabilistic sensitivity
analysis
QALY = quality-adjusted
life-year
QoL = quality of life
transient ischemic attack
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2729More recently, 4 nonwarfarin oral anticoagulants
(NOACs) (dabigatran, rivaroxaban, apixaban, and
edoxaban) were approved by the U.S. Food and Drug
Administration (FDA). As a group, they are noninferior
to warfarin for ischemic stroke reduction and superior
for hemorrhagic stroke and all-cause mortality, but
they have an increased risk for gastrointestinal
bleeding (4). As with warfarin, the effectiveness of
these drugs is contingent on patient adherence.
For patients who are poor candidates for long-term
oral anticoagulation, percutaneous left atrial
appendage closure (LAAC) is a device-based alterna-
tive for stroke prophylaxis in AF (5). The ﬁrst
FDA-approved LAAC device, the Watchman device
(Boston Scientiﬁc, Marlborough, Massachusetts), was
demonstrated to be noninferior to warfarin for
ischemic stroke reduction and superior for hemor-
rhagic stroke and all-cause mortality. However, it
is associated with procedure-related complica-
tions that predictably diminish in frequency with
operator experience (6). Importantly, most patients
can discontinue lifelong anticoagulation following
Watchman device implantation (6).SEE PAGE 2740Both clinical and economic value are important in
evaluating new therapies. Published U.S. economic
analyses have largely focused on the cost-
effectiveness of oral anticoagulants, and these
reports invariably use a lifetime analysis spanning
20 to 35 years (7–9). Herein, we estimate the cost-
effectiveness of all stroke prevention strategies
available in the United States at multiple points
over a lifetime horizon. Although both NOACs and
LAAC would initially be expected to be more costly
than warfarin, their clinical beneﬁts may supervene
with time, thereby altering cost-effectiveness. This
comprehensive assessment may aid clinicians and
health care decision makers in making informed
choices regarding patient treatment.
METHODS
A Markov model was developed in Excel to evaluate
the cost-effectiveness of 3 treatment strategies:
1. LAAC with the Watchman device (Boston
Scientiﬁc)
2. NOACs as a class
3. Adjusted-dose warfarin
The model was constructed from the perspective
of the Centers for Medicare & Medicaid Services
(CMS), with a lifetime horizon (deﬁned as 20 years)
and a 3-month cycle length. Within each cycle,patients could experience clinical events
leading to death, disability, and/or therapy
discontinuation and could incur associated
costs and QoL adjustments.
Cost-effectiveness was evaluated using
the U.S. accepted willingness-to-pay thres-
hold of $50,000 per quality-adjusted life-year
(QALY) gained, and it was reported as the
incremental cost-effectiveness ratio (ICER),
which provides a standardized approach
to measure cost per unit of health improve-
ment in and across health states. Cost-
effectiveness was assessed annually to
determine whether there was an observable
time horizon over which treatment options
reached accepted levels of cost-effectiveness.
MODEL STRUCTURE AND CLINICAL PATHWAYS. The
model beganwith patients assigned to 1 of 3 treatments
(Figures 1A and 1B). Patients in the LAAC arm faced a
1-time procedure-related risk, including ischemic
stroke resulting from air embolism (1.10%), major
bleeding (0.60%), and pericardial effusion (4.80%).
Patients undergoing LAAC could experience a suc-
cessful or failed implantation procedure. In accor-
dance with the PROTECT AF (Watchman Left Atrial
Appendage System for Embolic Protection in Patients
With Atrial Fibrillation) trial, patients who had suc-
cessful device implantation were assumed to receive
warfarin for 45 days, aspirin plus clopidogrel from 46
days to 6 months, and aspirin thereafter. Following a
failed procedure, patients were assumed to continue
warfarin therapy. Patients receiving warfarin or
NOACs could discontinue therapy following a bleeding
event or for nonclinical reasons. Patients who dis-
continued primary drug therapy were assumed to
switch to aspirin. Discontinuation of second-line
therapy was assumed to result in no treatment.
On entering the model, patients were assumed to
be “well,” or in normal, good health. Patients transi-
tioned to new health states following a clinical event
or death. Only ischemic and hemorrhagic stroke
affected disability outcomes. Patients who had a
second stroke could either remain in the same health
state or worsen to greater disability. Transient
ischemic attack (TIA) and systemic embolism led to
patients being well with a history of stroke, which
increased their risk of subsequent stroke. All events,
except TIA, could lead to death.
CLINICAL INPUTS. Clinical inputs were taken from
several sources (Table 1). For LAAC, procedural
complications and event probabilities were drawn
from PROTECT AF at 4-year follow-up (6). Relative
risks for post-procedural stroke and bleeding were
used to apply a standard efﬁcacy estimate to the
TIA =
FIGURE 1 Model Schematics Depicting LAAC and OAC Patient Pathways
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(A) Left atrial appendage closure (LAAC) decision nodes include procedural complications, implantation success, and subsequent outcomes. (B) Oral
anticoagulant (OAC) decision nodes include therapy discontinuation and subsequent outcomes.
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2730derived baseline risks. For warfarin, the relative risk
of stroke was derived from a meta-analysis of
warfarin trials (10). Risk data for all other
warfarin-related clinical events were estimated froma pooled analysis of multiple AF clinical trials
involving warfarin (4,16–20). NOAC clinical event
rates were derived from a NOAC meta-analysis and
from individual NOAC trials (4,12,13,21,22).
TABLE 1 Clinical Inputs Derived From Meta-Analyses and Pivotal Trials
Value Range Distribution Source (Ref. #)
LAAC
RR of post-procedure ischemic stroke
(relative to warfarin)
0.95 0.76–1.14* Lognormal Holmes et al., 2009;
Reddy et al., 2014 (5,6)
RR of hemorrhagic stroke (relative to warfarin) 0.15 0.03–0.49† Lognormal Reddy et al., 2014 (6)
RR of post-procedure major bleeding (relative to warfarin) 0.55 0.44–0.66 Lognormal Reddy et al., 2014 (6)
Annual risk of systemic embolism 0.20% 0.0%–0.4%† Beta Reddy et al., 2014 (6)
RR of myocardial infarction (relative to warfarin) 0.50 0.40–0.60 Lognormal Reddy et al., 2014 (6)
Risk of minor bleeding On the basis of concomitant drug therapy
Warfarin
RR of ischemic stroke (relative to no therapy) 0.33 0.23–0.46† Lognormal Hart et al., 2007 (10)
RR of major bleeding (relative to HAS-BLED) 1.00 0.80–1.20 Lognormal Pisters et al., 2010 (11)
Percentage of major bleeding that is
hemorrhagic stroke
41.80% 33.40%–50.20% Beta Ruff et al., 2014 (4)
Annual risk of systemic embolism 0.11% 0.90%–0.12%† Beta Connelly et al., 2009;
Granger et al., 2011 (12,13)
Annual risk of myocardial infarction 1.47% 0.53%–1.47%† Beta Ruff et al., 2014 (4)
Annual risk of minor bleeding 7.70% 0.80%–16.40% Beta Connelly et al., 2009;
Granger et al., 2011 (12,13)
NOACs
RR of ischemic stroke (relative to warfarin) 0.92 0.83–1.02† Lognormal Ruff et al., 2014 (4)
RR of hemorrhagic stroke (relative to warfarin) 0.48 0.39–0.59† Lognormal Ruff et al., 2014 (4)
RR of extracranial hemorrhage (relative to warfarin) 1.25 1.01–1.55† Lognormal Ruff et al., 2014 (4)
RR of systemic embolism 0.92 0.83–1.02† Lognormal Ruff et al., 2014 (4)
RR of myocardial infarction (relative to warfarin) 0.97 0.78–1.20† Lognormal Ruff et al., 2014 (4)
Annual risk of minor bleeding 8.70% 7.00%–10.40% Beta Connelly et al., 2009;
Granger et al., 2011 (12,13)
Aspirin
RR of ischemic stroke (relative to no therapy) 0.78 0.61–0.98† Lognormal Hart et al., 2007 (10)
RR of hemorrhagic stroke (relative to warfarin) 0.50 0.25–1.00† Lognormal Hart et al., 2007 (10)
RR of extracranial hemorrhage (relative to warfarin) 0.30 0.30–7.10 Lognormal Hart et al., 2007 (10)
Annual risk of systemic embolism 0.40% 0.30%–0.50% Beta ACTIVE A, 2009 (14)
RR of myocardial infarction (relative to warfarin) 2.00 1.60–2.40 Lognormal ACTIVE A, 2009;
ACTIVE W, 2006 (14,15)
Annual risk of minor bleeding 1.40% 1.00%–1.70% Beta ACTIVE A, 2009 (14)
No therapy
RR of ischemic stroke (relative to CHA2DS2-VASc score) 1.00 0.80–1.20 Lognormal Assumption on the basis
of no treatment
RR of major bleeding (relative to warfarin) 0.50 0.20–0.69† Lognormal SPINAF, CAFA, BAAFT (16–18)
RR of minor bleeding (relative to warfarin) 0.62 0.36–1.05† Lognormal SPINAF, CAFA, BAAFT (16–18)
RR of systemic embolism (relative to warfarin) 1.96 1.60–2.40 Lognormal CAFA (18)
RR of myocardial infarction (relative to warfarin) 1.00 0.80–1.20 Lognormal SPAF 1 (19)
Values are relative risks or risk percentages. *RR of post-procedural ischemic stroke (relative to warfarin) uses a range of 20% as the published 95% CI includes risk of
intraprocedure stroke. †Denotes 95% CI.
BAAFT ¼ Boston Area Anticoagulation Trial for Atrial Fibrillation; CAFA ¼ Canadian Atrial Fibrillation Anticoagulation; CHA2DS2-VASc ¼ congestive heart failure, hyper-
tension, age 75 years or older, diabetes mellitus, stroke–vascular disease; CI ¼ conﬁdence interval; HAS-BLED ¼ hypertension, abnormal renal/liver function, stroke, bleeding
history or predisposition, labile international normalized ratio, elderly (>65 years), drugs/alcohol concomitantly; LAAC ¼ left atrial appendage closure; NOAC ¼ nonwarfarin
oral anticoagulant; RR ¼ relative risk; SPAF 1 ¼ Stroke Prevention in Atrial Fibrillation; SPINAF ¼ Stroke Prevention in Nonrheumatic Atrial Fibrillation.
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2731Probabilities of death following systemic embo-
lism, extracranial hemorrhage, or myocardial infarc-
tion were derived from Healthcare Utilization Project
mortality rates for these diagnoses (23). Risk of death
from unrelated causes was obtained from U.S. life
tables, with disabled patients facing a 2.3-fold greater
risk of death (24,25).
Baseline risk of stroke was assigned according to
CHA2DS2-VASc (congestive heart failure, hypertension,age 75 years or older, diabetes mellitus, stroke–
vascular disease) scores, and risk of bleeding was
derived from HAS-BLED (hypertension, abnormal
renal/liver function, stroke, bleeding history or pre-
disposition, labile international normalized ratio,
elderly [>65 years], drugs/alcohol concomitantly)
scores (11,26). Because neither measure was prospec-
tively collected in the PROTECT AF or NOAC trials,
both were estimated using available baseline
TABLE 2 Stroke Outcomes and Health State Utilities
LAAC Warfarin (Ref. #) NOAC
Utility
Value
Nondisabling stroke
(MRS 0–2)
78.9 24.0 (16,17,19,20) 44.0 (12,13) 0.760 (33)
Moderately disabling
stroke (MRS 3)
5.3 29.0 (16,17,19,20) 21.4 (16,17,19,20) 0.390 (33)
Severely disabling stroke
(MRS 4–5)
5.3 35.0 (16,17,19,20) 25.8 (16,17,19,20) 0.110 (33)
Fatal stroke (MRS 6) 10.5 12.0 (16,17,19,20) 8.8 (16,17,19,20) 0.000
Values are percentages or utility values.
MRS ¼ modiﬁed Rankin score; other abbreviations as in Table 1.
TABLE 3 Cost Inputs
Acute Ev
LAAC procedure (includ
Fatal ischemic stroke
Severe ischemic stroke
Moderate ischemic stro
Minor ischemic stroke
Transient ischemic atta
Systemic embolism (no
Systemic embolism (fa
Fatal hemorrhagic stro
Severe hemorrhagic str
Moderate hemorrhagic
Minor hemorrhagic stro
Major extracranial hem
Major extracranial hem
Minor bleeding
Myocardial infarction (
Myocardial infarction (
Quarterly costs
Warfarin þ INR mon
NOAC
Independent post-st
Moderately disabled
Severely disabled po
*Costs for the LAAC proce
Weighting was obtained fr
18%/82% split across DRG
CPT ¼ Current Procedura
TEE ¼ transesophageal ech
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2732characteristic data from the trials. Patients were
assumed to be 70 years of age, with a mean CHA2DS2-
VASc score of 3.2 (annual stroke risk 3.4%), and a
HAS-BLED score of 2 (annual bleeding risk 1.88%)
(11,26). To account for increasing risk with age, rates
of ischemic and hemorrhagic stroke were increased by
1.4- and 1.97-fold per decade, respectively (27,28).
Patients experiencing a TIA or systemic embolism
were assumed to have a 2.6-fold higher risk of expe-
riencing a second ischemic event (28).ents Costs Code (Ref. #)
ing 2 TEEs)* $16,109 DRG 273/274 (43)
$8,854 DRG 063 (38)
$48,539 DRG 061/CMG 108–110 (38,39)
ke $33,235 DRG 062/CMG 101–104 (38,39)
$23,236 DRG 063/CMG 105–107 (38,39)
ck $4,097 DRG 069 (38)
nfatal) $4,924 DRG 068 (38)
tal) $8,520 DRG 067 (38)
ke $10,194 DRG 064 (38)
oke $42,562 DRG 064/CMG 108–110 (38,39)
stroke $28,595 DRG 065/CMG 101–104 (38,39)
ke $18,797 DRG 066/CMG 105–107 (38,39)
orrhage (nonfatal) $5,877 DRG 377 (38)
orrhage (fatal) $10,425 DRG 378 (38)
$427 CPT 42970 (44)
nonfatal) $6,862 DRG 280, 281, 282 (38)
fatal) $5,771 DRG 283, 284, 285 (38)
itoring $91 CPT 85610, 99211 (44,45)
$945 (45)
roke $108 CPT 99214 (44)
post-stroke $9,293 (40–42)
st-stroke $15,131 (40–42)
dure reﬂect 2016 Centers for Medicare & Medicaid Services reimbursement rates.
om 2012 U.S. hospital data (Healthcare Utilization Project [HCUP]) and reﬂects an
250 and 251 (24).
l Terminology; DRG ¼ diagnosis-related group; INR ¼ international normalized ratio;
ocardiogram; other abbreviations as in Table 1.HEALTH STATE UTILITIES AND STROKE OUTCOMES.
As is conventional in cost-effectiveness analyses, QoL
was captured in the model as health utility. Health
utility values were on a scale of 0 to 1, with 1 repre-
senting perfect health and 0 representing death.
Utility values for well with warfarin (0.987), well with
NOAC (0.994), and well with aspirin (0.998) are
consistent with values used in other AF stroke
reduction analyses (28–32). The utility value for well
with LAAC (0.999) was calculated by applying the
Nichol ordinary least squares (OLS) algorithm to Short
Form-12 (SF-12) data collected during PROTECT AF
(33,34). The utility weights for all well-based health
states were applied as a multiplying factor to an
underlying baseline utility of 0.82, representing QoL
at age 70 years (29). Baseline utility was decremented
by 2% per decade to account for general decline in
QoL with advancing age (35).
Because stroke is the most debilitating conse-
quence of AF, QoL also was assessed by stroke
severity. Stroke outcomes were assigned using the
modiﬁed Rankin score (MRS) and were character-
ized as nondisabling (MRS 0 to 2), moderately
disabling (MRS 3), severely disabling (MRS 4 to 5),
and fatal (MRS 6) (Table 2). Stroke outcomes for
LAAC were gathered from additional analyses of
PROTECT AF at 4 years. Warfarin stroke outcomes
were estimated using a weighted average of out-
comes from 4 warfarin trials (16,17,19,20). NOAC
stroke outcomes were derived from 2 of the
4 pivotal trials (12,13). Because only the rate of
nondisabling strokes was reported, the inverse
represented disabling and fatal strokes, with the
distribution of moderately disabling, severely dis-
abling, and fatal strokes assumed to be the same as
with warfarin.
Additionally, a series of disutilities was applied in
the model for acute clinical events, representing a
1-time decrement to QoL experienced for a ﬁnite
length of time. Utility decrements were assessed for
stroke (0.139), extracranial hemorrhage (0.181),
TIA (0.103), systemic embolism (0.120), and
myocardial infarction (0.125) (36). A value
of 0.0315 was used for the LAAC procedure itself,
which assumed a 2-week disruption to healthy life.
QALYs were calculated by multiplying the health
state utility value of each health state by the mean
time spent in the health state. Future QALYs were
discounted at an annual rate of 3% (37).
COSTS. The model incorporated all direct health
care costs for the therapies and treatment of asso-
ciated acute events, as well as costs for long-term
care following a disabling stroke (Table 3). Costs
TABLE 4 QALY and Cost Results at 5, 10, 15, and 20 Years
Total
QALYs
Incremental
QALYs
(Relative to
Warfarin)
Total
Costs
Incremental
Costs
(Relative to
Warfarin)
Incremental
Cost per QALY
Versus Warfarin
Incremental
Cost per QALY
Versus NOAC
5 yrs
LAAC 3.455 0.068 $20,892 $10,128 $149,468 Dominant
Warfarin 3.387 — $10,764 — — —
NOAC 3.448 0.061 $20,924 $10,160 $167,446 —
10 yrs
LAAC 5.855 0.254 $25,425 -$1,409 Dominant Dominant
Warfarin 5.601 — $26,834 — — —
NOAC 5.751 0.150 $39,260 $12,426 $82,684 —
15 yrs
LAAC 7.309 0.466 $29,075 -$12,251 Dominant Dominant
Warfarin 6.843 — $41,326 — — —
NOAC 7.077 0.234 $53,431 $12,105 $51,755 —
20 yrs
LAAC 8.031 0.638 $31,198 -$18,748 Dominant Dominant
Warfarin 7.392 — $49,946 — — —
NOAC 7.682 0.290 $61,701 $11,755 $40,602 —
QALY ¼ quality-adjusted life-year; other abbreviations as in Table 1.
J A C C V O L . 6 6 , N O . 2 4 , 2 0 1 5 Reddy et al.
D E C E M B E R 2 2 , 2 0 1 5 : 2 7 2 8 – 3 9 Time to Cost-Effectiveness Following AF Treatment
2733for acute events were taken from U.S. 2015
diagnosis-related group (DRG) national average
values, and costs for post-stroke inpatient rehabili-
tation were from 2015 case-mix group (CMG) reim-
bursement rates (38,39). Long-term stroke disability
costs were obtained from previous publications
(30–32,40–42).
LAAC procedure costs were calculated as a
weighted average of the 2 newly created DRGs for
percutaneous intracardiac procedures (273 and 274),
plus the cost of 2 follow-up transesophageal echo-
cardiograms (43,44). The annual cost of warfarin
therapy was also applied for LAAC-treated patients
who were unable to discontinue warfarin. Warfarin
costs were from U.S. pharmaceutical wholesale
acquisition data, in combination with reimbursement
rates for Current Procedural Terminology (CPT) codes
related to international normalized ratio monitoring
(44,45). NOAC costs were calculated as an average of
U.S. wholesale acquisition costs for the ﬁrst 3
approved drugs: dabigatran, rivaroxaban, and apix-
aban (45). All costs, with the exception of LAAC pro-
cedure costs, are in 2015 U.S. dollars and are
discounted at an annual rate of 3%.
SENSITIVITY ANALYSIS. To assess the impact of
parameter uncertainty on model results, 1-way
sensitivity analysis and probabilistic sensitivity
analysis (PSA) were undertaken. One-way sensi-
tivity analysis reveals which inputs have the great-
est impact on results, and PSA generates thousands
of outcomes by using varied inputs to allow esti-
mation of the effect of individual parameter un-
certainty on uncertainty around model results (46).
Inputs were varied within 95% conﬁdence intervals
(CIs), where available, and by 20% where CIs were
not published. Additionally, the impact of LAAC
procedure cost was explored independently, with
100% variation. Table 1 shows ranges and distribu-
tions used for clinical inputs. Stroke outcomes
assumed a Dirichlet distribution, and health state
utilities assumed a beta distribution. All costs were
varied by 20% and assumed a gamma distribution.
The PSA followed a standard Monte Carlo approach
on the basis of 5,000 randomly drawn simulations
of parameter values.
RESULTS
LAAC VERSUS WARFARIN. As expected, LAAC was
more expensive than warfarin in the ﬁrst post-
procedure year, and patients had fewer QALYs because
of the disutility applied for the procedure (Table 4,
Central Illustration). By year 3, LAAC-treated patientsgained more QALYs than did warfarin-treated patients
(0.015). LAAC became cost-effective relative to
warfarin by year 7, with a cost per QALY gained of
$42,994. By year 10, LAAC was dominant (more effec-
tive and less costly) over warfarin and remained so
throughout the remainder of the 20-year time horizon.
Over a lifetime, LAAC provided an additional
0.506 life-years and 0.638 QALYs relative to warfarin.
Online Figure 1 shows the total QALYs for all 3 treat-
ment groups over 20 years.
NOACs VERSUS WARFARIN. NOACs were more
effective than warfarin in year 1 and achieved
cost-effectiveness relative to warfarin at year 16
($48,446/QALY). NOACs were not cost saving relative
to warfarin over 20 years, although the ICER
continued to decrease over time, such that the cost
per QALY at 20 years was $40,602.
LAAC VERSUS NOACs. When comparing LAAC with
NOACs, LAAC was expectedly more expensive than
NOACs in the ﬁrst post-procedure year. However, by
year 5, LAAC was less expensive ($20,892 vs. $20,924)
and more effective (3.455 vs. 3.448 QALYs) than
NOACs. LAAC remained dominant over NOACs
throughout the modeled time horizon. Over a pa-
tient’s lifetime, LAAC was estimated to provide an
additional 0.298 life-years and 0.349 QALYs relative
to NOACs.
ONE-WAY SENSITIVITY ANALYSIS. Tornado dia-
grams illustrating the 10 most impactful variables in
descending order of inﬂuence at 20 years are depicted
CENTRAL ILLUSTRATION Warfarin Versus NOACs Versus LAAC: Cumulative Cost and Time to Cost-Effectiveness Following
Treatment Initiation
(Incremental QALYs)                                 (Cost per QALY)                 (More Effective, Less Costly)S      
LAAC vs. NOACs                                                                                                                                                 Year 5
Time to Clinical Effectiveness Time to Cost-Effectiveness             Time to Dominance
 (More Effective, Le s Costly)
LAAC vs. warfarin                                                                                                                                             Year 10 Year 3                                               Year 7(0.015)                                       ($42,994/QALY)
  Year 1                                              Year 16
(0.008)                                  ($48,446/QALY)
  Year 5                                              Year 5
(0.007)                                        (Dominant)
NOACs vs. warfarin                                                                                                                                              N/A
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Reddy, V.Y. et al. J Am Coll Cardiol. 2015; 66(24):2728–39.
(Upper panel) Average total cumulative costs per patient over 20 years. Left atrial appendage closure (LAAC) becomes less costly than nonwarfarin oral
anticoagulants (NOACs) at 5 years and less costly than warfarin at 10 years. (Lower panel) Summary of time to clinical and cost-effectiveness for each
treatment arm. LAAC becomes cost-effective at 7 years relative to warfarin and at 5 years relative to NOACs. NOACs achieve cost-effectiveness relative to
warfarin at 16 years. QALY ¼ quality-adjusted life-year.
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2734in Figure 2 (Online Figures 2A to 2C for 10-year re-
sults). One-way sensitivity analyses of LAAC versus
warfarin demonstrated that the health utility values
used for well with LAAC had a signiﬁcant impact on
model results, with this being the only variable for
which the upper threshold increased the ICER at
20 years beyond $50,000/QALY (Figure 2A). The
baseline risk of ischemic stroke also inﬂuenced the
ICER, with higher risks resulting in more favorable
cost-effectiveness for LAAC. All other variables had
a <1% impact on model outcomes. When comparing
LAAC with NOACs (Figure 2B), the 20-year results
were most sensitive to the utility values for well with
LAAC and well with NOACs along with the baseline
risk of bleeding. However, only varying well with
LAAC increased the ICER beyond the $50,000threshold. In the NOAC versus warfarin analysis
(Figure 2C), the baseline risk of bleeding had the
greatest impact on modeled results, followed by the
utility value for well with NOAC, baseline risk of
stroke, and the proportion of NOAC ischemic strokes
that were severely disabling.
Additional analyses demonstrated that, even with
a doubling of LAAC procedure cost, LAAC remained
cost-effective. As expected, time to cost-effectiveness
increased, with LAAC becoming cost-effective at 11
years relative to warfarin ($41,470/QALY) and at 10
years relative to NOACs ($21,964/QALY); however,
LAAC remained dominant over both drug compara-
tors over the lifetime analysis.
PROBABILISTIC SENSITIVITY ANALYSIS. PSA simu-
lations (Figure 3) demonstrated that LAAC had
FIGURE 2 Tornado Plots of 1-Way Sensitivity Analyses at 20 Years of LAAC Versus Warfarin, LAAC Versus NOACs, and NOACs
Versus Warfarin
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(A) LAAC versus warfarin. (B) LAAC versus nonwarfarin oral anticoagulants (NOACs). (C) NOACs versus warfarin. The 10 most impactful var-
iables are presented in descending order of inﬂuence. All were varied, in standard fashion, as published 95% conﬁdence intervals or 20%.
HS ¼ hemorrhagic stroke; ICH ¼ intracranial hemorrhage; IS ¼ ischemic stroke.
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FIGURE 3 Scatter Plots of Incremental Costs and Incremental QALYs at 20 Years for LAAC Versus Warfarin, LAAC Versus NOACs, and NOACs
Versus Warfarin
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Probabilistic sensitivity analysis results reﬂect 5,000 model simulations to estimate the effect of uncertainty on model results. QALYs ¼ quality-adjusted
life-years; other abbreviations as in Figures 1 and 2.
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2736lower average total costs than warfarin and NOACs
at 20 years: $31,127 (95% CI: $17,350 to $51,067)
versus $48,817 (95% CI: $28,719 to $77,484) versus
$58,254 (95% CI: $44,865 to $77,763). Over 20 years,
there was a 94% probability that LAAC was cost
saving relative to warfarin, a 97% probability that
LAAC provided more QALYs, and a 100% probability
that it provided more life-years. The overall proba-
bility of cost-effectiveness was 98%, using a
willingness-to-pay threshold of $50,000/QALY. At
20 years, there was a 95% probability that LAAC
was cost-effective relative to NOACs and a 75%
probability that NOACs were cost-effective relative towarfarin. Similar outcomes, albeit with greater scat-
ter, are seen when the PSAs were conducted at 10
years (Online Figures 3A to 3C).
DISCUSSION
This analysis demonstrates that both novel thera-
pies, NOACs and LAAC with the Watchman device,
are cost-effective relative to warfarin for stroke risk
reduction in patients with nonvalvular AF. When
compared over a lifetime, LAAC proved to be the
most cost-effective treatment. LAAC becomes cost-
effective relative to warfarin at 7 years, with an
J A C C V O L . 6 6 , N O . 2 4 , 2 0 1 5 Reddy et al.
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2737ICER of $42,994. In contrast, NOACs require twice
as long to achieve cost-effectiveness relative to
warfarin, with an ICER of $48,446. LAAC was less
costly than warfarin at 10 years and NOACs at 5
years, with cost savings generated annually there-
after. NOACs are more effective than warfarin, but
they remain more expensive throughout the life-
time horizon.
Sensitivity analyses suggest that these cost-
effectiveness results are robust and not overly
sensitive to variation in individual parameters, with
the exception of well with LAAC, well with NOACs,
and baseline risk of bleeding. Speciﬁcally, 1-way
sensitivity analyses found that LAAC is more cost-
effective in patients at higher risk of stroke and
bleeding. Given the importance of baseline utility
values in this analysis, future prospective studies of
these novel therapies should evaluate QoL over
time. PSA indicates a high probability that LAAC is
cost saving relative to warfarin and NOACs over
20 years.
Although costs of any new health intervention
must be considered, patient outcomes remain of
paramount importance. Cost-effectiveness modeling
uses 1 metric to account for cost, clinical effective-
ness, and patient outcomes. For stroke prevention,
the risk and cost of stroke are highly important, but so
too are QoL and functional outcomes following
stroke. Indeed, a preference study of stroke outcomes
revealed that most patients rate severe disability as
worse than death (47).
LAAC-treated patients experienced fewer
disabling strokes than did patients taking warfarin
or NOACs: 79% of strokes in patients who had un-
dergone LAAC resulted in an MRS score of 0 to 2
versus 24% of strokes in patients taking warfarin
and 44% of strokes in patients taking NOACs. This
ﬁnding suggests that most LAAC-treated patients
can return to daily life without assistance following
stroke, whereas more than one-half the patients
who have a stroke while taking oral anticoagulants
require lifetime assistance. Furthermore, previously
published SF-12 data collected during PROTECT AF
found an overall improvement in QoL and physical
functioning in LAAC-treated patients relative to
warfarin-treated patients at 12 months (34).
Disability following a stroke has long-term implica-
tions for both patients and health care costs, thus
warranting further study.
NOACs offer signiﬁcant advantages over warfarin,
but the problem of therapy adherence persists.
Analysis of Medicare MarketScan data found that only
38% to 40% of patients with AF who had a moderate
to high risk of stroke received a prescription foranticoagulation therapy, and 46% of these patients
had a gap in anticoagulation therapy during the 2
years analyzed (48). Additionally, 63% of all stroke-
related hospitalizations occurred in patients who
were not receiving oral anticoagulation. With nearly
$8 billion spent annually on AF-associated strokes (3),
improving adherence is crucial to reducing this cost
burden.
By its very nature, LAAC is not subject to patient
adherence issues. Once implanted, the device pro-
vides lifelong stroke prophylaxis without the risk of
complications associated with oral anticoagulants.
Although the procedure has risks, they are reduced
with operator experience. In recognition of the clin-
ical risk/beneﬁt relationship, the 2014 American
Heart Association/American Stroke Association
updated guidelines include consideration of LAAC in
patients at high risk for stroke who are “unsuitable”
for long-term anticoagulation, if they can tolerate the
risk of at least 45 days of post-procedural anti-
coagulation (49).
To the best of our knowledge, the only other study
assessing the cost-effectiveness of LAAC in the
United States was published in abstract form. In this
study, LAAC dominated all NOACs, except for the
110-mg dose of dabigatran, and was cost-effective,
but not cost saving relative to warfarin (50). This
difference from our analysis is likely explained by our
detailed patient-level accounting of stroke severity
and QoL. A cost-effectiveness analysis for the Cana-
dian health system compared LAAC with Watchman,
dabigatran, and warfarin (51). Despite overall con-
clusions directionally consistent with our analysis
(particularly both LAAC and dabigatran cost-
effectiveness relative to warfarin and LAAC domi-
nance over dabigatran), the earlier analysis had
several limitations. First, only 1.5-year follow-up
PROTECT AF data were used, versus 3.8-year
follow-up data in our present analysis. Second,
whereas only dabigatran outcomes were available at
that time, the present analysis additionally in-
corporates outcomes with rivaroxaban, apixaban, and
edoxaban. Third, whereas that earlier analysis
examined only a lifetime horizon, the present anal-
ysis considers cost-effectiveness at multiple time
points. Finally, the present analysis uses a U.S. payer
perspective.
STUDY LIMITATIONS. Our model allowed for only 1
clinical event per 3-month cycle, whereas multiple
events may occur. Data were taken from multiple
sources, including meta-analyses and randomized
controlled trials. Individual trials had different time
horizons, and all data were extrapolated to 20 years.
PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE:
As an alternative to long-term warfarin therapy for
stroke prophylaxis in patients with AF who are poor
candidates for long-term anticoagulation, percuta-
neous LAAC become cost-effective at 7 years. On the
basis of current cost estimates, LAAC would be asso-
ciated with more QALYs gained by 10 years than
warfarin or NOACs.
TRANSLATIONAL OUTLOOK: Longer-term clinical
studies are needed to deﬁne more clearly the return
on investment in nonpharmacologic strategies to
prevent stroke in patients with AF and incorporate the
ﬁndings into clinical practice guidelines and reim-
bursement policies.
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2738By necessity, an indirect comparison method was
used, with warfarin as the common control value.
Although this methodology is well established in
health economic analyses (52), these data are not
derived from a direct, randomized comparison. How-
ever, it will likely be many years before an LAAC
versus NOAC randomized trial is performed. Addi-
tionally, the datasets from which probabilities were
drawn were all on the basis of intention-to-treat an-
alyses, whereas the model allowed for the possibility
of therapy change. Finally, treatments administered
in clinical practice may vary in effectiveness
compared with that observed in randomized trials,
which generally enroll selected patients, achieve
higher levels of adherence, and monitor patients more
intensively.
CONCLUSIONS
Both NOACs and LAAC with the Watchman
device have the potential to change the treatment
paradigm for patients with nonvalvular AF who
are at risk of stroke. Both novel therapies demon-
strated cost-effectiveness relative to warfarin,
but only LAAC demonstrated cost savings by year 10
relative to warfarin and by year 5 relative to NOACs.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Vivek Y. Reddy, Helmsley Trust, Electrophysiology
Center, Icahn School of Medicine at Mount Sinai,
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